Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
Titel:
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
Auteur:
Twardowski, Przemyslaw W. Tangen, Catherine M. Wu, Xiwei Plets, Melissa R. Plimack, Elizabeth R. Agarwal, Neeraj Vogelzang, Nicholas J. Wang, Jinhui Tao, Shu Thompson, Ian M. Lara, Primo